| 1 |
32803289 | Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms. | 2021 Jan |
1 |
| 2 |
30471066 | Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. | 2019 Aug |
1 |
| 3 |
27149910 | Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. | 2016 Jun |
6 |
| 4 |
23432535 | Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study. | 2013 May-Jun |
1 |
| 5 |
23700791 | Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects. | 2013 Apr |
2 |
| 6 |
20514078 | Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. | 2011 Aug |
5 |
| 7 |
21356216 | Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. | 2011 Apr 11 |
1 |
| 8 |
18589174 | Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. | 2008 Jun |
2 |
| 9 |
16024008 | Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. | 2005 Dec |
2 |
| 10 |
15377640 | Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. | 2004 Oct |
2 |
| 11 |
15499178 | CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. | 2004 Apr |
3 |